DexCom
DXCM
Collegium Pharmaceutical
COLL
Lantheus
LNTH
Cars.com
CARS
YETI Holdings
YETI
US Stock MarketDetailed Quotes
LIPO Lipella Pharmaceuticals
- 3.170
- -0.010-0.31%
Close Jan 3 16:00 ET
- 3.290
- +0.120+3.79%
Post 19:59 ET
3.83MMarket Cap-0.74P/E (TTM)
3.260High3.060Low33.27KVolume3.210Open3.180Pre Close105.83KTurnover3.90%Turnover RatioLossP/E (Static)1.21MShares12.00052wk High2.63P/B2.71MFloat Cap2.21052wk Low--Dividend TTM853.80KShs Float61.760Historical High--Div YieldTTM6.29%Amplitude2.210Historical Low3.181Avg Price1Lot Size
Lipella Pharmaceuticals News
Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating
Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating, Maintains Target Price $2
Buy Rating on Lipella Pharmaceuticals Backed by Promising Phase 2a Results for Oral Lichen Planus Treatment
Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating, Maintains Target Price $2
Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating, Maintains Target Price $2
Buy Rating Affirmed: Lipella Pharmaceuticals' Innovative Drug Delivery and Clinical Advancements Propel Optimism
Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating, Maintains Target Price $2
Buy Rating Affirmed for Lipella Pharmaceuticals on LP-310's Phase 2a Enrollment and Strategic Advantages
Analysts Are Bullish on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Lipella Pharmaceuticals, Inc. (LIPO)
Lipella Pharmaceuticals Analyst Ratings
No More